A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 8, 2006, Pages 936-962

  Keeffe, Emmet B ^a   Dieterich, Douglas T ^b   Han, Steven Huy B ^d   Jacobson, Ira M ^e   Martin, Paul ^c   Schiff, Eugene R ^f   Tobias, Hillel ^g   Wright, Teresa L ^h  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CREATININE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS E ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TENOFOVIR; VIRUS DNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANOREXIA; BACTERIAL INFECTION; BIOASSAY; CANCER SCREENING; CAUSE OF DEATH; CHRONIC HEPATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FATIGUE; FLU LIKE SYNDROME; GENE MUTATION; GENOTYPE; HEALTH CARE COST; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATEMIA; INCIDENCE; LEUKOPENIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL EXPERT; MEDICAL SPECIALIST; MORTALITY; NEPHROTOXICITY; NEWBORN DEATH; NOMENCLATURE; PATIENT ASSESSMENT; PATIENT MONITORING; POPULATION RESEARCH; PREGNANCY; PREVALENCE; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SCIENTIFIC LITERATURE; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRUS MUTANT;

ALGORITHMS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MUTATION; PATIENT SELECTION;

EID: 33746339209     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.05.016     Document Type: Review

References (171)

1. Keeffe E.B., Dieterich D.T., Han S.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the U.S. Clin Gastroenterol Hepatol 2 (2004) 87-106
2. Lok A.S., and McMahon B. Chronic hepatitis B. update of recommendations. Hepatology 39 (2004) 857-861
3. Liaw Y.F., Leung N., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. a 2005 update. Liver Int 25 (2005) 472-489
4. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 (2003) S3-S25
5. Lee W. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
6. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States. the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89 (1999) 14-18
7. U.S. Census Bureau. State and County Quickfacts: 01 February 2005. Available: http://quickfacts.census.gov/qfd/states/00000.html. Accessed: September 20, 2005.
8. Guane R., Siu O., Lam K., et al. Prevalence of HBV acquisition in hepatitis B screening programs in large metropolitan cities in the Unites States. (abstr). Hepatology 40 (2004) 716A
9. Sherman A., Tsang T., Villaneuva G., et al. Mass screenings in New York City reveal extraordinarily high prevalence of hepatitis B in an urban Asian population. (abstr). Hepatology 42 (2005) 214A
10. CDC. Incidence of acute hepatitis B-United States, 1990-2002. MMWR Morb Mortal Wkly Rep 52 (2004) 1252-1254
11. www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm. Accessed: April 9, 2006.
12. Poterucha J.J., and Wiesner R.H. Liver transplantation and hepatitis B. Ann Intern Med 126 (1997) 805-807
13. McMahon B.J., Alward W.L.M., Hall D.B., et al. Acute hepatitis B virus infection. relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
14. Tassopoulos N.C., Papaevangelou G.J., Sjogren M.H., et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 92 (1987) 1844-1850
15. Lok A.S., Heathcote E.J., and Hoofnagle J.H. Management of hepatitis B. 2000-summary of a workshop. Gastroenterology 120 (2001) 1828-1853
16. Di Bisceglie A.M., Waggoner J.G., and Hoofnagle J.H. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology 93 (1987) 1236-1241
17. Hsu Y.S., Chien R.N., Yeh C.T., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35 (2002) 1522-1527
18. Perrillo R.P. Acute flares in chronic hepatitis B. the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009-1022
19. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
20. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
21. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B. a multicenter study. J Hepatol 21 (1994) 656-666
22. de Jongh F.E., Janssen H.L., de Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
23. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 21 (1995) 77-82
24. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
25. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
26. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
27. Hadziyannis S.J., Lieberman H.M., Karvountzis G.G., et al. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus HBV DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 3 (1983) 656-662
28. Carman W.F., Jacyna M.R., Hadziyannis S., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2 (1989) 588-591
29. Okamoto H., Tsuda F., Akahane Y., et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68 (1994) 8102-8110
30. Hadziyannis S.J. Hepatitis B e antigen negative chronic hepatitis B. from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1 (1995) 7-36
31. Hadziyannis S.J., and Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34 (2001) 617-624
32. Hadziyannis S.J., Bramou T., Alexopoulou A., et al. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: Hollinger F.B., Lemon S.M., and Margolis H.S. (Eds). Viral hepatitis and liver disease (1991), Williams & Wilkins, Baltimore 673-676
33. Brunetto M.R., Giarin M.M., Oliveri F., et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 88 (1991) 4186-4190
34. Tenney D.J., Langley D.R., Oliver A.J., et al. Hepatitis B virus resistance to entecavir involves novel changes to the viral polymerase. (abstr). Hepatology 41 (2004) 245A
35. Kidd-Ljunggren K., Miyakawa Y., and Kidd A.H. Genetic variability in hepatitis B viruses. J Gen Virol 83 (2002) 1267-1280
36. Kramvis A., and Kew M.C. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12 (2005) 456-464
37. Chu C.J., and Lok A.S. Clinical significance of hepatitis B virus genotypes. Hepatology 35 (2002) 1274-1276
38. Kao J.H., Chen P.J., Lai M.Y., et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 40 (2002) 1207-1209
39. Fujie H., Moriya K., Shintani Y., et al. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 120 (2001) 1564-1565
40. Chu C.J., Hussain M., and Lok A.S. Hepatitis B virus genotype B is associated with earlier seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122 (2002) 1756-1762
41. Kao J.H., Wu N.H., Chen P.J., et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33 (2000) 998-1002
42. Zhang X., Zoulim F., Habersetzer F., et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 48 (1996) 8-16
43. Lau G.K., Piratvisuth Y.T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
44. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B. a randomised trial. Lancet 365 (2005) 123-129
45. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
46. Chu C.J., Hussain M., and Lok A.S.F. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36 (2002) 1408-1415
47. Lindh M., and Hannoun C. Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real time semiautomated assay. J Clin Microbiol 43 (2005) 4251-4254
48. Saldanha J., Gerlich W., Leslie N., et al. A international collaborative study to establish a World Health Organization standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 80 (2001) 63-71
49. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
50. Wang C., Deubner H., Shuhart M., et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection. (abstr). Hepatology 42 (2005) 573A
51. Nguyen M.H., Trinh H., Garcia R.T., et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. (abstr). Hepatology 42 (2005) 593A
52. Lai M., Hyatt B., and Afdahl N. Role of liver biopsy in patients with normal ALT and high HBV DNA. (abstr). Hepatology 42 (2005) 720A
53. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-9
54. Kim H.C., Nam C.N., Jee S.H., et al. Normal serum aminotransferase concentration and risk of mortality from liver disease. prospective cohort study. BMJ 328 (2004) 983-989
55. Poynard T., Zoulim F., Ratzui V., et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 100 (2005) 1970-1980
56. Beasley R.P. Hepatitis B virus. the major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
57. McMahon B.J. Hepatocellular carcinoma and viral hepatitis. In: Wilson R.A. (Ed). Viral hepatitis (1997), Marcel Dekker, New York 315-330
58. Johnson P.J., and Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma. influence of therapy and possible value in early detection. J Cancer Inst 64 (1980) 1329-1332
59. Sheu J.C., Sung J.L., Chen D.S., et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89 (1985) 259-266
60. Sherman M., Peltekian K.M., and Lee C.L. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus. incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22 (1995) 432-437
61. Sheu J.C., Sung J.L., Chen D.S., et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. Cancer 56 (1985) 660-666
62. Zoli M., Magalotti D., Bianchi G., et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 78 (1996) 977-985
63. Oka H., Kurioka N., Kim K., et al. Prospective study of early detection of hepatocellular carcinoma. Cancer 12 (1990) 680-687
64. Cottone M., Turri M., Caltagirone M., et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis. an 8 year prospective study by ultrasound and alpha-fetoprotein. J Hepatol 21 (1994) 1029-1034
65. Colombo M., De Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 (1991) 675-680
66. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
67. McMahon B.J., Bulkow L., and Harpster A. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B. a 16-year population-based study. Hepatology 32 (2000) 842-846
68. Puoti C., Magrini A., Stati T., et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26 (1997) 1393-1398
69. Chien R.N., Liaw Y.F., and Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30 (1999) 770-774
70. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
71. 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2 (1988) 298-302
72. Lok A.S.F., Wu P.C., Lai C.L., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 (1992) 2091-2097
73. Marcellin P., Chang T.T., Lim S.G., et al. Baseline ALT predicts histologic and serological response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV). (abstr). J Hepatol 37 (2002) 39
74. Hoofnagle J.H., Dusheiko G.M., Seeff L.B., et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 94 (1981) 744-748
75. Fattovich G., Rugge M., Brollo L., et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 6 (1986) 167-172
76. Werle B., Wursthorn K., Petersen J., et al. Quantitative analysis of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy. an international multicenter study. (abstr). Hepatology 36 (2002) 296A
77. Bréchot C., Thiers V., Kremsdorf D., et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen. clinically significant or purely "occult"?. Hepatology 34 (2001) 194-203
78. Conjeevaram H.S., and Lok A.S. Occult hepatitis B virus infection. a hidden menace?. Hepatology 34 (2001) 204-206
79. Mommeja-Marin H., Mondou E., Blum R., et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection. analysis and review of the literature. Hepatology 37 (2002) 1309-1319
80. Manesis E.K., Papatheodoridis G.V., Sevastianos V., et al. Significance of hepatitis H viraemia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98; (2003) 2261-2267
81. Lok A.S., and Lai C.L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 8 (1988) 1130-1133
82. Chang M.H., Hsu H.Y., Hsu H.C., et al. The significance of spontaneous hepatitis B e antigen seroconversion in childhood. with special emphasis on the clearance of hepatitis e antigen before 3 years of age. Hepatology 22 (1995) 1387-1392
83. Lok A.S.F., Lai C.L., Wu P.C., et al. Spontaneous hepatitis e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 (1987) 1839-1843
84. Lee P.I., Chang M.H., Lee C.Y., et al. Changes in serum hepatitis B DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 12 (1990) 657-660
85. Lok A.S.F., and Lai C.L. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. incidence, predisposing factors and etiology. J Hepatol 10 (1990) 29-34
86. Yuen M.F., Hui C.K., Cheng C.C., et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection. the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
87. Bortolotti F., Cadrobbi P., Crivellaro C., et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood. Gastroenterology 99 (1990) 805-810
88. Marcellin P., Chang T., Lim S., et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. (abstr). J Hepatol 42 (2005) 31
89. Hadziyannis S., Tassopoulos N., Chang T.T., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B. results after 5 years of therapy. (abstr). Hepatology 42 (2005) 754A
90. Locarnini S., Qi W., Arterburn S., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). (abstr). J Hepatol 42 (2005) 17
91. Angus P., Vaughn R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
92. Chang T., Gish R., De Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
93. Gish R.G., Chang T.T., De Man R.A., et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). (abstr). Hepatology 42 (2005) 267A
94. Colonno R., Rose R., Levine S., et al. Entecavir two year resistance update. no resistance observed in nucleoside naïve patients and low frequency resistance emergence in lamivudine refractory patients. (abstr). Hepatology 42 (2005) 573A-574A
95. Hoofnagle J.H. Hepatitis B-preventable and now treatable. N Engl J Med 345 (2006) 1074-1076
96. Wong D.K.H., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 119 (1993) 312-323
97. Schiff E.R. Treatment algorithms for hepatitis B and C. Gut 34 (1993) S148-S149
98. Bortolotti F., Jara P., Barbera C., et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 46 (2000) 715-718
99. Fattovich G., Giustina G., Sanchez-Tapias J., et al. Delayed clearance of serum HBsAg in compensated cirrhosis B. relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 93 (1998) 896-900
100. Hoofnagle J.H., and DiBisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 336 (1997) 347-356
101. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B virus in the United States. N Engl J Med 341 (1999) 1256-1263
102. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B virus infection. a randomised trial. Gut 46 (2000) 562-568
103. Liaw Y.F., Leung N.W.Y., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
104. Leung N.W.Y., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates. results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
105. Chang T.T., Lai C.L., Liaw Y.F., et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antivir Ther 5 Suppl 1 (2000) 44
106. Guan R., Lai C.L., Liaw Y.F., et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 (2001) A60-A61
107. Liaw YF. Results of lamivudine in Asian trials. Proceedings of EASL International Consensus Conference on Hepatitis B: 2002 September 13-14; Geneva. Geneva: European Association for the Study of the Liver.
108. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
109. Liaw Y. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 17 (2002) S333-S337
110. Barbarini G., Zechini F., Pellicelli A., et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. an Italian multicenter randomized trial. (abstr). Hepatology 34 (2001) 318A
111. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Eng J Med 351 (2004) 1206-1217
112. Lau G., Cooksley H., Ribeiro R.M., et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg+ chronic hepatitis B. efficacy and mechanisms of treatment response. (abstr). Hepatology 40 (2004) 272A
113. Sung J.J.Y., Lai Y.F., Zeuzem S., et al. A randomised, double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for the treatment of naïve patients with chronic hepatitis B (CHB). week 52 analysis. (abstr). J Hepatol 38 (2003) 25
114. Korenman J., Baker B., Waggoner J., et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
115. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 5 (1998) 389-397
116. Lin S.M., Sheen I.S., Chien R.N., et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
117. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
118. Lok A.S., Chung H.T., Liu V.W., et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105 (1993) 1833-1838
119. Dienstag J.L., Cianciara J., Karayalcin S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
120. Song B.C., Suh D.J., Lee H.C., et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
121. Ryu S.H., Chung Y.H., Choi M.H., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss. a prospective study. J Hepatol 39 (2003) 614-619
122. Chang T.T., Shiffman M., Tong M., et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B. (abstr). J Hepatol 40 (2004) 126
123. Gish R.G., Martin P., Schiff E.R., et al. Entecavir leads to sustained response off-treatment in nucleoside-naive HBeAg(+) patients who met on-treatment response endpoints at 48 weeks of therapy in phase 3 study ETV-022. (abstr). Gastroenterology 128 (2005) A692-A693
124. Brook M.G., Karayiannis P., and Thomas H.C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10 (1989) 761-763
125. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
126. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1026
127. Manesis E.K., and Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121 (2001) 101-109
128. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
129. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients. a long term cohort study. J Hepatol 36 (2002) 263-270
130. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29 (1999) 889-896
131. Santantonio T., Mazzola M., Iacovazzi T., et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 (2000) 300-306
132. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
133. Fung S.K., Wong F., Hussain M., et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 11 (2004) 432-438
134. Buti M., Cotrina M., Jardi R., et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 8 (2001) 270-275
135. Locarnini S., Hatzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
136. Perrillo R., Rakela J., Dienstag J., et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29 (1999) 1581-1586
137. Atkins M., Hunt C.M., Brown N., et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients. (abstr). Hepatology 28 (1998) 319A
138. Peters M., Hann H.W., Martin P., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistance and chronic hepatitis B. Gastroenterology 126 (2004) 91-101
139. Lee Y.S., Suh D.J., Lim Y.S., et al. Emergence of rtA181V/T and rtN236T mutations after 48 weeks of adefovir dipivoxil therapy in patients with lamivudine-resistant chronic hepatitis B. (abstr). Hepatology 42 (2005) 578A
140. Lok A.S., Fung S.K., Han S.H., et al. Virological response and resistance to adefovir (ADV) therapy in liver transplant (OLT) patients. (abstr). Hepatology 42 (2005) 232A
141. Ghany M., Lutchman G., Kleiner D., et al. Lamivudine and adefovir versus adefovir alone for HBeAg-positive chronic hepatitis B. (abstr). Hepatology 42 (2005) 591A-592A
142. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory HBeAg+ chronic hepatitis B. results of phase III study ETV-026. (abstr). Hepatology 40 (2004) 664A
143. Schiff E.R., Lai C.L., Neuhaus P., et al. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine resistant (LAM-R) hepatitis B virus (HBV). (abstr). Hepatology 36 (2002) 371A
144. Schiff E., Lai C.L., Neuhaus P., et al. Adefovir dipivoxil (ADV) provides significant clinical benefit, reduces MELD score and prevents transplantation in chronic hepatitis B patients wait-listed for liver transplantations (OLT) with lamivudine resistance (LAM-R). (abstr). J Hepatol 42 (2005) 5
145. Perrillo R., Hann H.W., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
146. Hoofnagle J.H., DiBisceglie A.M., Waggoner J.G., et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (1993) 1116-1121
147. Perrillo R., Tamburro C., Regenstein F., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109 (1995) 908-916
148. Liaw Y.F., Sung J.J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
149. Perrillo R.P., Wright T., Rakela J., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
150. Villeneuve J.P., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31 (2000) 207-210
151. Schiff E., Lee W.M., Chao Y.C., et al. Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated cirrhotic patients with chronic hepatitis B. (abstr). Hepatology 42 (2005) 583A-584A
152. Yuen M.F., Sablon E., Yuan H.J., et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 37 (2003) 562-567
153. Homann C., Krogsgaard K., Pedersen C., et al. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 4 (1991) 416-420
154. Thio C.L., Seaberg E.C., Skolasky Jr. R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 360 (2002) 1921-1926
155. Benhamou Y., Bochet M., Thibault V., et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus. an open-label pilot study. Lancet 358 (2001) 718-723
156. Benhamou Y., Thibault V., Calvez V., et al. 3-year treatment with adefovir dipivoxil in chronic hepatitis B patients with lamivudine-resistant HBV/HIV co-infection, results in significant and sustained clinical improvement (2004) (abstr 835). XIth Conference on Retroviruses and Opportunistic Infections
157. Pessoa W., Gazzard B., Huang A., et al. Entecavir in HIV/HBV co-infected patients. safety and efficacy in a phase II study (ETV-038) (2005) (abstr 123). XIIth Conference on Retroviruses and Opportunistic Infections
158. Benhamou Y., Katlama C., Lunel F., et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125 (1996) 705-712
159. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30 (1999) 1302-1306
160. Cooper D., Cheng A., Coakley D., et al. Anti-hepatitis B virus (HBV) activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected patients (2002) (abstr 6015). 14th International AIDS Conference, Barcelona
161. Benhamou Y., Bochet M., Tubiana R., et al. Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV (2002) (abstr 7527). 14th International AIDS Conference, Barcelona
162. Van Bommel F., Mauss S., Wunsche T., et al. Frequency of HBeAg loss and long-term antiviral suppression under nucleos(t)ide treatment in HBeAg positive chronic hepatitis B. (abstr). J Hepatol 42 (2005) 193
163. Reynes J., Peyrière H., Merle De Boever C., et al. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy (2003) (abstr 717). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA
164. Blick G., Greiger-Zanlungo P., Garton T., et al. Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis (2003) (abstr 718). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA
165. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease. a French survey of 6,664 patients. Hepatology 26 (1997) 485-490
166. Crockett S.D., and Keeffe E.B. Natural history and treatment of patients coinfected with hepatitis B and hepatitis C viruses. Ann Clin Microbiol Antibicrob 4 (2005) 13
167. Liu C.J., Chen P.J., Lai M.Y., et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 37 (2002) 568-576
168. Simpson N.D., Simpson P.W., Ahmed A.M., et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 37 (2003) 68-71
169. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
170. Van Zonneveld M., Van Nunen A.B., Niesters H.G., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10 (2003) 294-297
171. Xu W.M., Cui Y.T., Wang L., et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B. a multicenter, randomised, double-blind, placebo-controlled study. (abstr). Hepatology 40 (2004) 272A-273A